Re-use of Open Data and Data science: Industry, Institutions

Read More

 

 

Comparative effectiveness Research: Mixed Treatment Comparisons, Network Meta-Analysis

Read More

 

 

Health Economics Modeling and Pricing (HAS CEESP, CEPS)

Read More

 

Statistical Analysis of Real Life Data

Read More

 

Welcome

Statésia is a research and consulting firm specialized in comparative effectiveness research and medico-economic analysis of health products, technologies and strategies (for HAS CT, HAS CEESP, CEPS submissions).

Our competitive advantage is founded on a strong collaborative action with the Applied Mathematics Research team of the University of Maine (EA 3263), for performing suitable modeling techniques.

This decision analysis is founded on:

1- Comparative Effectiveness Research, Indirect and Mixed Treatment Comparisons (MTC) : Positioning your innovative technology in the studied therapeutic area;

2- Interactive Health Economics Modeling: Assessing the cost-effectiveness, the cost-utility or the cost-benefit of your innovative health product or technology;

3- Interactive Budget Impact Analysis (IBIA) : Assessing the affordability of your innovative product.

 

 

 

FaLang translation system by Faboba

News

Franck Maunoury provided a review for International Task Force SDM-ISPOR /Value of Information /VOINOVEMBER, 2017, Paris.

Statésia provided a training session in two parts about 1. The propensity score, and 2. The expected value of perfect information (EVPI) for a pharmaceutical laboratory: JUNE, 2017, Paris.

Publication: F Maunoury1 Aide à la decision des modèles médico-économiques (article méthodologique). Journal de Gestion etd'Economie Médicales (JGEM) 2016/2 (Vol. 34) Pages 177-186; DOI: 10.3917/jgem.162.0177. Editeur ESKA

Statésia took part in an early meeting with the SEESP department (HAS) about the cost-effectiveness modelling of a new health product for the CEESP dossier (HAS): NOVEMBER, 2016. Haute Autorité de santé (HAS), Paris.

Statésia yielded a technical report about the cost-effectiveness modelling of a new health product for the CEESP dossier (HAS): MAY, 2016. Haute Autorité de santé (HAS), Paris.

Statésia participated in a early meeting with the SEESP department (HAS): JANUARY, 2016. Haute Autorité de santé (HAS), Paris.

top arrow